Teladoc Health, Inc.

As of June 30, 2026, Teladoc Health, Inc. carries a market capitalization of 26.15B, placing it among publicly traded companies globally. Its enterprise value stands at 30.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Teladoc Health, Inc.'s next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Teladoc Health, Inc. has 181.65M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.59, and the price-to-book ratio stands at 1.14.

As of June 30, 2026, Teladoc Health, Inc. trades at an EV/EBITDA multiple of 9.20 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 30.73B versus a market cap of 26.15B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Teladoc Health, Inc. maintains a current ratio of 0.83, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.09, indicating elevated leverage, while an interest coverage ratio of 9.58 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Teladoc Health, Inc. posted a negative return on equity (ROE) of -12.99, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.28, reflecting losses generated across the asset base. The company generates approximately 7.80M in revenue per employee across its workforce of 5,575.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 23.07 indicates how many times Teladoc Health, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Teladoc Health, Inc. recorded an income tax benefit of -90.82M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -3.19B and -3.10B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Teladoc Health, Inc.'s stock has declined approximately 24.85% over the past 52 weeks. The 50-day moving average sits at 119.05, while the 200-day moving average is 129.06.

Over the twelve months ended June 30, 2026, Teladoc Health, Inc. generated 43.50B in revenue and converted that into -3.10B in net income, yielding earnings per share of -17.34. EBITDA reached 3.34B, while operating income came in at -2.54B.

As of June 30, 2026, Teladoc Health, Inc. holds 13.53B in cash and equivalents against 18.10B in total debt, resulting in a net debt position of 3.88B. Total book value stands at 22.89B, with working capital of -4.08B providing operational flexibility.

Teladoc Health, Inc. produced 4.56B in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled 4.56B - equivalent to 25.53 per share.

Over the twelve months ended June 30, 2026, Teladoc Health, Inc. posted a gross margin of 68.97, reflecting its pricing power and cost economics. The operating margin of -5.85 and net profit margin of -7.13 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 17.74, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.27, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Teladoc Health, Inc. shareholders.

As of June 30, 2026, Teladoc Health, Inc. has an Altman Z-Score of -15.86, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.